ADDITIONAL EFFECTS OF WEIGHT LOSS DRUGS
Weight loss treatment has been revolutionised by the introduction of highly effective medications such as semaglutide (marketed as Wegovy and Ozempic) and tirzepatide (Mounjaro).
W
hile initially developed to manage type 2 diabetes, these drugs have demonstrated exceptional weight-loss
capabilities. Beyond just helping people shed excess pounds, they offer a variety of additional health benefits. New research suggests that these medications contribute to improved cardiovascular health, enhanced kidney function and even potential neuroprotective effects.
The Science Behind Weight Loss Drugs Most of the new generation of weight loss drugs work by mimicking hormones that regulate appetite and blood sugar. Specifically, semaglutide and tirzepatide act as glucagon-like peptide-1 (GLP-1) receptor agonists, enhancing insulin secretion, slowing digestion and reducing hunger. This mechanism allows individuals to eat less without experiencing intense cravings, leading to significant weight loss over time.
A recent study found that individuals taking these drugs experienced a 15% to 20% reduction in body weight, a result that was previously achievable only through bariatric surgery. This weight reduction, in turn, has far-reaching health benefits beyond aesthetic improvements.1
Positive Side Effects & Health Benefits
1. Cardiovascular Health Improvements Obesity is a significant risk factor for cardiovascular diseases, including heart attacks and strokes. Recent clinical trials have shown that weight loss drugs do more than just reduce body weight—they also improve heart health. A study published in 2023 demonstrated that semaglutide significantly lowers the risk of major cardiovascular events. 1
The primary reason behind this effect is the reduction in blood pressure and cholesterol levels that accompanies weight loss. Additionally, GLP-1 receptor agonists have been found to exert direct protective effects on the heart, reducing inflammation and improving arterial function.2
In addition to preventing heart disease, these drugs have also been linked to improved overall vascular function. By reducing systemic inflammation and enhancing circulation, GLP-1 receptor agonists may lower the risk of blood clots and other complications associated with poor vascular health.3
2. Enhanced Kidney Function Chronic Kidney Disease (CKD) is a common complication of obesity and diabetes, leading to
44
pharmacyinfocus.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48
